Visium Asset Management’s PTC Therapeutics PTCT Stock Holding History

Visium Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-204,554	Closed	-$1.32M	–	461
2016 Q1	$1.32M	Buy	+204,554	New	+$3.55M	0.02%	419
2015 Q3	–	Sell	-21,971	Closed	-$1.06M	–	1133
2015 Q2	$1.06M	Buy	+21,971	New	+$1.28M	0.02%	518
2014 Q1	–	Sell	-50,000	Closed	-$848K	–	1000
2013 Q4	$848K	Sell	50,000 -600	-1%	-$10.5K	0.02%	474
2013 Q3	$1.09M	Buy	+50,600	New	+$879K	0.02%	409

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Visium Asset Management's PTCT Position: Q2 2016 in Review

Visium Asset Management sold out of PTC Therapeutics (PTCT) in Q2 2016, closing a stake of 204,554 shares — an estimated $1.32M sold.

Visium Asset Management first reported a position in PTCT in Q3 2013 and held it in 4 quarters. The position peaked at $1.32M in Q1 2016. 118 funds tracked by Wall St. Rank hold PTCT as of Q2 2016.

Visium Asset Management reported no remaining PTC Therapeutics position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 204,554 PTC Therapeutics shares in Q2 2016, an estimated $1.32M.
Visium Asset Management first reported a position in PTC Therapeutics in Q3 2013 and held it in 4 quarters.
Visium Asset Management's PTC Therapeutics position peaked at $1.32M in Q1 2016.
118 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.